Intuitive Surgical, Inc. $ISRG Shares Sold by Banque Transatlantique SA

Banque Transatlantique SA lowered its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 5.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 151,383 shares of the medical equipment provider’s stock after selling 8,748 shares during the quarter. Intuitive Surgical accounts for approximately 2.1% of Banque Transatlantique SA’s investment portfolio, making the stock its 11th largest position. Banque Transatlantique SA’s holdings in Intuitive Surgical were worth $85,881,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. State Street Corp lifted its holdings in Intuitive Surgical by 1.0% in the 4th quarter. State Street Corp now owns 15,701,591 shares of the medical equipment provider’s stock valued at $8,892,753,000 after acquiring an additional 162,264 shares during the last quarter. Capital World Investors grew its stake in shares of Intuitive Surgical by 1.7% in the 4th quarter. Capital World Investors now owns 7,856,018 shares of the medical equipment provider’s stock worth $4,449,491,000 after purchasing an additional 127,526 shares during the last quarter. Norges Bank acquired a new position in shares of Intuitive Surgical in the 4th quarter worth approximately $2,856,987,000. Invesco Ltd. raised its holdings in shares of Intuitive Surgical by 17.4% in the 4th quarter. Invesco Ltd. now owns 4,128,735 shares of the medical equipment provider’s stock worth $2,338,350,000 after purchasing an additional 611,268 shares in the last quarter. Finally, Fisher Asset Management LLC raised its holdings in shares of Intuitive Surgical by 1.1% in the 3rd quarter. Fisher Asset Management LLC now owns 3,889,439 shares of the medical equipment provider’s stock worth $1,739,475,000 after purchasing an additional 40,702 shares in the last quarter. 83.64% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently weighed in on ISRG. Wall Street Zen upgraded shares of Intuitive Surgical from a “hold” rating to a “buy” rating in a report on Saturday, June 13th. Zacks Research cut Intuitive Surgical from a “strong-buy” rating to a “hold” rating in a report on Monday, March 30th. JPMorgan Chase & Co. cut their price objective on Intuitive Surgical from $625.00 to $550.00 and set an “overweight” rating for the company in a research report on Wednesday, April 22nd. The Goldman Sachs Group set a $558.00 price objective on Intuitive Surgical in a research note on Wednesday, May 27th. Finally, Truist Financial decreased their target price on Intuitive Surgical from $650.00 to $580.00 and set a “buy” rating on the stock in a report on Wednesday, April 15th. Nineteen analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $573.42.

Insider Transactions at Intuitive Surgical

In related news, SVP Iman Jeddi sold 5,625 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $420.55, for a total transaction of $2,365,593.75. Following the transaction, the senior vice president directly owned 6,463 shares of the company’s stock, valued at approximately $2,718,014.65. The trade was a 46.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Amy L. Ladd sold 119 shares of the stock in a transaction dated Wednesday, April 29th. The stock was sold at an average price of $463.50, for a total value of $55,156.50. Following the completion of the sale, the director directly owned 120 shares of the company’s stock, valued at approximately $55,620. This represents a 49.79% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 7,169 shares of company stock valued at $3,059,135 over the last quarter. Company insiders own 0.60% of the company’s stock.

Intuitive Surgical Stock Performance

Shares of NASDAQ:ISRG opened at $406.78 on Friday. The firm has a 50 day simple moving average of $439.54 and a 200 day simple moving average of $491.05. Intuitive Surgical, Inc. has a 52 week low of $396.68 and a 52 week high of $603.88. The company has a market cap of $144.07 billion, a PE ratio of 49.31, a price-to-earnings-growth ratio of 3.27 and a beta of 1.46.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Tuesday, April 21st. The medical equipment provider reported $2.50 earnings per share for the quarter, topping the consensus estimate of $2.08 by $0.42. Intuitive Surgical had a net margin of 28.15% and a return on equity of 15.98%. The firm had revenue of $2.77 billion for the quarter, compared to analysts’ expectations of $2.62 billion. During the same period in the previous year, the company posted $1.81 EPS. The company’s quarterly revenue was up 23.0% compared to the same quarter last year. On average, equities analysts predict that Intuitive Surgical, Inc. will post 8.57 earnings per share for the current year.

Intuitive Surgical Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.